S L Pett

Summary

Affiliation: University of New South Wales
Country: Australia

Publications

  1. pmc Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Med 12:219-27. 2011
  2. ncbi request reprint A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    AIDS Res Hum Retroviruses 26:653-61. 2010
  3. ncbi request reprint Role of interleukin-2 in patients with HIV infection
    Sarah L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    Drugs 70:1115-30. 2010
  4. doi request reprint Immunotherapies in HIV-1 infection
    Sarah L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, New South Wales 2010, Australia
    Curr Opin HIV AIDS 4:188-93. 2009
  5. ncbi request reprint A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 14:111-5. 2009
  6. ncbi request reprint Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Clin Trials 7:70-85. 2006
  7. ncbi request reprint Cytokine therapies in HIV-1 infection: present and future
    Sarah L Pett
    University of New South Wales, National Centre in HIV Epidemiology and Clinical Research, Level 2, 376, Victoria Street, Darlinghurst, NSW 2010, Australia
    Expert Rev Anti Infect Ther 1:83-96. 2003
  8. ncbi request reprint A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services, St Vincent s Hospital, Sydney, and National Centre in HIV Epidemiology and Clinical Research, University of NSW, Darlinghurst, Sydney, Australia
    HIV Clin Trials 5:91-8. 2004
  9. ncbi request reprint Immunomodulators as adjunctive therapy for HIV-1 infection
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
    J Clin Virol 22:289-95. 2001
  10. ncbi request reprint Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine
    K Suzuki
    Centre for Immunology, St Vincent s Hospital, Sydney, NSW 2010, Australia
    AIDS Res Hum Retroviruses 17:1293-6. 2001

Detail Information

Publications13

  1. pmc Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Med 12:219-27. 2011
    ..cART alone (control arm) in HIV-infected adults with CD4 counts ≥300cells/μL, offered the opportunity to explore associations between bacterial pneumonia and rIL-2, a cytokine that increases the risk of some bacterial infections...
  2. ncbi request reprint A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    AIDS Res Hum Retroviruses 26:653-61. 2010
    ..The persistence and clinical meaning of these immunological changes during long-term exposure to this class of anti-HIV drugs are unknown, but may have implications for immunosurveillance of inflammation...
  3. ncbi request reprint Role of interleukin-2 in patients with HIV infection
    Sarah L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
    Drugs 70:1115-30. 2010
    ..Moreover, there was an excess of grade 4 clinical events in ESPRIT rIL-2 recipients. The results of the phase III clinical endpoint studies showed that rIL-2 has no place as a therapeutic agent in the treatment of HIV infection...
  4. doi request reprint Immunotherapies in HIV-1 infection
    Sarah L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, New South Wales 2010, Australia
    Curr Opin HIV AIDS 4:188-93. 2009
    ..This review is timely, as the results of the phase III clinical trials of recombinant interleukin-2 (rIL-2) as adjuncts to combination antiretroviral therapy are about to be released...
  5. ncbi request reprint A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 14:111-5. 2009
    ..SCH532706 is a novel small molecule chemokine receptor-5 (CCRS) antagonist with high in vitro potency (mean 90% inhibitory concentration [IC90] 0.15-7.0 nM) against diverse HIV type-1 (HIV-1) isolates...
  6. ncbi request reprint Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Clin Trials 7:70-85. 2006
    ..Objectives: To describe the baseline characteristics of participants randomized to ESPRIT overall and by geographic location...
  7. ncbi request reprint Cytokine therapies in HIV-1 infection: present and future
    Sarah L Pett
    University of New South Wales, National Centre in HIV Epidemiology and Clinical Research, Level 2, 376, Victoria Street, Darlinghurst, NSW 2010, Australia
    Expert Rev Anti Infect Ther 1:83-96. 2003
    ..Cytokines and therapeutic vaccination have been proposed as HAART-adjunctive and HAART-sparing treatments in HIV-infection, and the current and future role of cytokine therapy in this disease will be the subject of this review...
  8. ncbi request reprint A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals
    Sarah L Pett
    HIV, Immunology and Infectious Diseases Clinical Services, St Vincent s Hospital, Sydney, and National Centre in HIV Epidemiology and Clinical Research, University of NSW, Darlinghurst, Sydney, Australia
    HIV Clin Trials 5:91-8. 2004
    ..To establish the pharmacokinetics and safety of single-dose polyclonal caprine anti-HIV antibodies ((PE)HRG214)in HIV-1-infected individuals...
  9. ncbi request reprint Immunomodulators as adjunctive therapy for HIV-1 infection
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
    J Clin Virol 22:289-95. 2001
    ..However, the immunological competency and therefore clinical impact of this expanded CD4(+) T cell pool is yet to be established; this question is the focus of two large clinical end-point studies, ESPRIT and SILCAAT...
  10. ncbi request reprint Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine
    K Suzuki
    Centre for Immunology, St Vincent s Hospital, Sydney, NSW 2010, Australia
    AIDS Res Hum Retroviruses 17:1293-6. 2001
    ..Our findings provide evidence that the deletion of RT residue 69 selectively confers high-level NVP resistance...
  11. ncbi request reprint Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1
    Sarah L Pett
    AIDS 16:2364-5. 2002
  12. ncbi request reprint Antiretroviral therapy-induced immune restoration in HIV infection: a double-edged sword?
    Sarah L Pett
    Expert Rev Anti Infect Ther 2:335-9. 2004
  13. ncbi request reprint Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials
    Alan R Lifson
    Department of Epidemiology and Community Health, University of Minnesota, 1300 South Second Street, Minneapolis, MN 55454, USA
    HIV Clin Trials 7:125-41. 2006
    ..The processes for reporting and review of progression of HIV disease clinical endpoints are described for two large phase III international clinical trials...